August 18-19, 2021 | Virtual Event

ALL TIMES ARE IN EASTERN TIME

Speakers will be available for Q&A and further dialogue within their respective ‘Meet The Speaker’ Break Out Roundtables: A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!

Over the past year, there have been changes in the M&A and legal landscape across the life science industry. While gene therapies are still a heavily involved market it is important to understand the new policy the FDA has on the interpretation of orphan drugs vs. gene therapy products. Part of the new developments are the increase use of documentation for diligence efforts.
  • Understand the differences between pharma, medical device, and digital ‘diligence’
  • Explore data privacy and the access to data, understand how it’s being stored and giving access and questions
  • Analyze how digital therapeutics enhance the internal process to enhance patient interaction and satisfaction
Anu Daniel
Director, Due Diligence
SANOFI
  • Act as a point of contact for business development colleagues for recruitment of the appropriate expertise within the safety community to address due diligence requests
  • Establish ways of working between safety functions to optimize use of resources for due diligence activities
  • Develop training and provide support on the due diligence process for the safety community
Tom Chu
Principal Medical Safety Director
GENENTECH
Allow for the movement into smaller groups of your industry peers based upon the respective topics, and aligning your shared interests/expertise. A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but also with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!

Meet The Speaker Roundtable For The 10:05 Session Meet The Speaker Roundtable For The 10:25  Session

Anu Daniel
Director, Due Diligence
SANOFI
Meet The Speaker Roundtable For The 10:50  Session

Tom Chu
Principal Medical Safety Director
GENENTECH
 
  • Adapt the collaboration tools and techniques that are used and evolved over the years
  • Virtually ensure your team understand the project and their roles
  • Create a personable experience even when it’s not face to face
  • Align your internal and external team members
Teresa Faria
Senior Director, Alliance Management
DAIICHI SANKYO
  • Understand the importance of creating a manufacturing checklist to contain operational financial, and economic due diligence
  • Mitigate risk by understanding revenue forecasts, working with capital needs and understand future cash flow through internal and external teams such as supply chain
  • Dissect the due diligence challenges in the pharma acquirer or collaborator
  • Discuss how Diligence effects how you transact
  • Understand what diligence impacts what is important to you in CMC and IPR
  • Evaluate the ability to do this through warranty diligence and transactions
Neil Berkley
Vice President, Head of Business Development
HALOZYME THERAPEUTICS

Lizabeth Leveille
Vice President, BD&L, Head, Boston & European Innovation Hubs
MERCK RESEARCH LABORATORIES
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!

Meet The Speaker Roundtable For The 11:30  Session

Teresa Faria
Senior Director, Alliance Management
DAIICHI SANKYO
Meet The Speakers Roundtable For The 11:50 Session Meet The Speaker Roundtable For The 12:50  Session

Neil Berkley
Vice President, Head of Business Development
HALOZYME THERAPEUTICS

Lizabeth Leveille
Vice President, BD&L, Head, Boston & European Innovation Hubs
MERCK RESEARCH LABORATORIES
  • Understanding the role third parties play in delivering technology enablement and innovation and how to manage risk and reputation
  • Learn best practices on how to maintain third party relationships through cloud based technologies
  • Optimizing your business and aligning internal risk and compliance management teams   
  • Understanding approaches for a successful expansion OUS (introduction to the options by using a local agent, a distributor, a partner, a licensee, a direct customer, etc)
  • Discuss due diligence levels according to the types of commercial partnerships in emerging markets (this way I can go over the DD activities depending on what approach is selected from bullet point 1 above) manufacturer, etc…)
  • When to transform your product and how to prepare for it (this would focus on considerations such as labeling, stability, bioequivalence, packaging configurations, etc… as well as distribution channels such as registered product, named patient, vital/not available, special access, etc)
Oscar Riano
Director, Key Accounts
MALLINCKRODT PHARMACEUTICALS
  • Examine the value of the target companies secrets
  • Determining the company’s strengths and weaknesses
  • Leveraging marketing strategies and timelines of it use and trademarks
Allow for the movement into smaller groups of your industry peers based upon the respective topics, and aligning your shared interests/expertise. A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but also with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!

Meet The Speaker Roundtable for 1:30 Session Meet The Speaker Roundtable for 1:50 Session

Oscar Riano
Director, Key Accounts
MALLINCKRODT PHARMACEUTICALS
Meet The Speaker Roundtable for 2:10 Session
Speakers will be available for Q&A and further dialogue within their respective ‘Meet The Speaker’ Break Out Roundtables: A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!

  • Informing your perspective on the opportunity with the right toolkit
  • Benchmarking those perspectives against a relevant standard
  • Weighing relative benefits/risks of perspectives
  • Building an aligned recommendation
Scott Simmons
Advisor, External Innovation – Due Diligence
ELI LILLY AND COMPANY
  • Review relevant background material of both the acquiring and target enterprises
  • Understanding business rational and drivers
  • Understanding the business integration model, scope, in the expected contributions
Tayseer Ghazzouli
Senior Director, Head of Alliance Management & IC Support
JANSSEN

Somjeet Dey
Business Development and Alliance Management
OTSUKA PHARMACEUTICALS
  • The drive to decrease the expansion of pipelines, but to advance and replenish them
  • Addressing the problem of declining R&D productivity which can help M&A to be used as an avenue to raise the growth of the R&D cost
  • Address challenges and opportunities of diversification; joint ventures, alliances, and licensing deals; and emerging markets
Tushar Nuwal
Vice President, Business Development & Licensing and Alliance Management
POLYPID
Allow for the movement into smaller groups of your industry peers based upon the respective topics, and aligning your shared interests/expertise. A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but also with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!

Meet The Speaker Roundtable for 10:00 Session

Scott Simmons
Advisor, External Innovation – Due Diligence
ELI LILLY AND COMPANY
Meet The Speaker Roundtable for 10:20 Session

Tayseer Ghazzouli
Senior Director, Head of Alliance Management & IC Support
JANSSEN

Somjeet Dey
Business Development and Alliance Management
OTSUKA PHARMACEUTICALS
Meet The Speaker Roundtable for 10:40 Session

Tushar Nuwal
Vice President, Business Development & Licensing and Alliance Management
POLYPID
  • Taking a systematic approach to increase numbers and incorporate them into routine of clinical operations
  • Understand best practices on how your DTx teams should be developing their digital treatments
  • Understand how gene therapies are advancing and driving M&A deals
  • Looking beyond the transaction and analyzing the costs associated with the protection of the IP post closing
  • Identifying competitors through similar trademarks
  • Incorporate your company’s IP assets into your diligence
Kenneth Jaconetty
Senior Director, Intellectual Property, Legal Lead For Intellectual Property Transactions
ASTELLAS
  • Validate your target and understand how to reach them
  • Evaluate your business development opportunities for strategic partnerships and external sources of innovation
Tushar Nuwal
Vice President, Business Development & Licensing and Alliance Management
POLYPID
  • Developing the due diligence approach and the action plan by executing the  performing assessments across the main functional areas
  • Conducting a robust due diligence process to avoid risks considerations
Meet The Speaker Roundtable for 11:20 Session Meet The Speaker Roundtable for 11:40 Session

Kenneth Jaconetty
Senior Director, Intellectual Property, Legal Lead For Intellectual Property Transactions
ASTELLAS
Meet The Speaker Roundtable for 12:10 Session

Tushar Nuwal
Vice President, Business Development & Licensing and Alliance Management
POLYPID
While the world is focusing on those companies who are in the race for developing and creating COVID vaccines and therapeutics IPOs in biotechs and he life science industry has increased significantly

  • Explore what SPAC professionals can do to mitigate their litigation exposure
  • Evaluate negotiations and ways to conduct due diligence in SPAC and IPO trades
  • Understanding how to find an asset that is reasonably priced when deal making turns challenging from venture capitalists
  • Explore how companies are performing due diligence with venture capitalists virtually and the plan for when they can meet in person
  • Defining the scope and priority focus areas for the due diligence and M&A effort
Meet The Speaker Roundtable for 1:25 Session Meet The Speaker Roundtable for 1:45 Session